The drug is known as T-DM1, and if approved, could hit the market as early as next year, according to an article by The New York Times.
The new
drug represents an advance in treating breast cancer, and the success in the clinical
trials show that it’s possible to deliver the drug to cancerous cells while at
the same time saving healthy ones.
T-DM1
and other similar drugs being tested consist of antibodies, which are powerful
toxins linked to proteins. The antibodies from the drugs grab on to cancer
cells and directly deliver the toxins to it.
Side
effects of the drugs are reduced as the toxins are not active until it reaches
the tumor.
In the trials, it
was seen that T-DM1 delayed the worsening of breast cancer by about three
months. Also, approximately 85 percent of patients receiving the new drug were
still alive after one year, compared to the control group which had a
percentage of 77.
Snyder and Wenner, P.C.
2200 E. Camelback Road
Suite 213
Phoenix, AZ 85016
602-224-0005
No comments:
Post a Comment